Lv5
860 积分 2022-10-26 加入
Homogeneous Dual-Payload Antibody-Drug Conjugates Produced by Combined Distinct Conjugation Strategies
6天前
已完结
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
12天前
已完结
Fcγ receptors and immunomodulatory antibodies in cancer
22天前
已完结
Considerations for the Identification and Conveyance of Clinical Pathology Findings in Preclinical Toxicity Studies: Results From the 9th ESTP International Expert Workshop
30天前
已完结
Toxicologic Pathology Forum*: Opinion on the Interpretation of Statistical Significance Testing Results From Anatomic and Clinical Pathology Data in Nonclinical Safety Studies
30天前
已完结
Toxicologic Pathology Forum*: Opinion on Qualitative Severity Descriptors to Express Magnitude of Changes in Clinical Pathology Endpoints in Nonclinical Toxicity Studies
30天前
已完结
大疱性类天疱疮诊疗专家共识(2025版)
1个月前
已完结
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)
1个月前
已完结
大疱性类天疱疮诊疗专家共识(2025版)
1个月前
已关闭
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
皖公网安备34019202002308
